Rationale: Misregulation of angiotensin II (Ang II) actions can lead to atherosclerosis and hypertension. Evaluating transcriptomic responses to Ang II in vascular smooth muscle cells (VSMCs) is important to understand the gene networks regulated by Ang II, which might uncover previously unidentified mechanisms and new therapeutic targets.
C ardiovascular diseases (CVDs), such as hypertension and atherosclerosis, are associated with several pathophysiological changes that include hyperproliferation and hypertrophy of vascular smooth muscle cells (VSMCs) within the blood vessel wall. 1 Fundamental to the development of these pathologies is angiotensin II (Ang II), a small polypeptide hormone that promotes many processes, including vasoconstriction, inflammation, fibrosis, and cellular growth. 2 The type 1 receptor and the type 2 receptor mediate Ang II signaling. Ang II binding to type 1 receptor results in most of its pathological effects. [1] [2] [3] [4] [5] [6] Angiotensin-converting enzyme inhibitors, which reduce Ang II availability, and type 1 receptor blockers have been effective in reducing blood pressure and renal disease in patients and animal models, highlighting the importance of Ang II in the pathogenesis of cardiovascular and renal complications. 7, 8 At the cellular level, VSMCs treated with Ang II increase expression of proinflammatory and profibrotic genes, including monocyte chemoattractant protein-1 (Mcp-1, also known as Ccl2), interleukin-6 (Il-6), and plasminogen activator inhibitor-1 (Pai-1). Additionally, extracellular matrix genes, such as collagen and fibronectin, are also induced by Ang II 1, 4, 6, [9] [10] [11] ; however, the molecular mechanisms that mediate the cellular response to Ang II and, ultimately, the pathogenesis of CVDs are not fully clear.
Recent studies have begun to elucidate the role of noncoding RNAs in VSMC biology. miRNAs are short noncoding RNAs that have been shown to be important for VSMC proliferation, differentiation, and contractility. [12] [13] [14] Recently, we characterized specific miRNAs that are involved in mediating inflammatory and fibrotic responses of VSMCs to Ang II. 15 It has recently become apparent that, in addition to small RNAs, many long noncoding transcripts (lncRNAs) function in a variety of responses, which include differentiation, cell cycle, and maintenance of stem-cell-like phenotypes, and are cell-type specific in their expression. [16] [17] [18] [19] [20] [21] [22] [23] Yet, very little is known about their regulation or roles in disease states. RNAsequencing (RNA-seq) has recently been applied to assess the transcriptome of normal and failing murine hearts of mice to discover lncRNAs that may be involved. 24 However, it is not known whether lncRNAs have a role in VSMCs or in the actions of Ang II because a comprehensive analysis of the VSMC transcriptome in response to Ang II has not yet been performed. Therefore, a thorough investigation of transcripts regulated by Ang II is important to further understand the molecular mechanisms that drive CVDs.
In this study, we sought to identify novel lncRNAs in the rat genome that may play a role in the response of VSMCs to Ang II. We performed RNA-seq followed by de novo assembly of transcripts from rat VSMCs and identified previously unannotated transcripts. A large number of these novel transcripts have limited protein-coding potential, which we classified as lncRNAs. We profiled histone H3-lysine-4 trimethylation (H3K4me3) and histone H3-lysine-36 trimethylation (H3K36me3), 2 epigenetic chromatin modifications associated with active transcription, 21 genome-wide with chromatinimmunoprecipitation sequencing (ChIP-seq) and discovered that the majority of genomic regions with novel transcripts, both protein-coding and noncoding RNAs, are enriched for these modifications. This suggests that the novel transcripts identified are bona fide transcripts.
We next identified 491 transcripts that are differentially expressed in response to Ang II, including 14 novel protein-coding transcripts and 24 novel lncRNAs. Many of the lncRNAs are located proximal to other Ang II-regulated genes, suggesting that they may be coregulated in response to Ang II. An lncRNA, Lnc-Ang362, is proximal to 2 miRNAs, miR-222 and miR-221, which have been previously associated with regulating VSMC proliferation and Ang II actions in endothelial cells. 25, 26 Lnc-Ang362 and the 2 mature miRNAs are similarly upregulated in response to Ang II in VSMCs. Knockdown of Lnc-Ang362 reduces the expression of the miRNAs, indicating that miRNAs are coregulated with the lncRNA. Furthermore, we observed that a reduction of Lnc-Ang362 transcript level is associated with a decrease in cell proliferation, suggesting that it plays a role in cell growth. The differential expression of Lnc-Ang362 and the mature miRNAs with Ang II treatment is also supported by ex vivo experiments.
Taken together, our studies reveal genome-wide changes in gene expression and key histone modifications in Ang IItreated VSMCs that have led to the first identification of novel protein-coding transcripts and lncRNAs that may function in Ang II-mediated cellular responses. The data also reveal that an lncRNA functionally acts as a host transcript for 2 miR-NAs with key pathological effects in VSMCs. Given that the rat genome is much less annotated than the human or mouse, our data also provide new insights into this valuable animal model.
Methods

Cell Culture and Ang II Treatment of VSMCs
Animal studies were approved by the Institutional Animal Care and Use Committee and performed according to approved protocols. VSMCs were isolated and cultured as previously described. 3, 9 Ang II (0.1 μmol/L, Bachem)-treated cells were processed for RNA extraction or chromatin-immunoprecipitation experiments. For ex vivo analyses, aortas were isolated from male rats, the adventitial layers were removed and split for control and Ang II treatment. For RNA analysis, aortas were homogenized with bead beating.
RNA-Sequencing
RNA was extracted from cells using Trizol (Invitrogen). RNA (2 μg) was depleted of ribosomal RNA (Ribominus, Invitrogen). Eluted RNA was prepared for sequencing using Illumina protocols, and then sequenced on the HiSeq 2000 (Illumina) to generate 2×80 bp pairedend reads. We obtained 86 mol/L and 80 mol/L reads for 2 controls (independent biological replicates) and 88.9 mol/L and 89 mol/L reads for 2 Ang II-treated VSMCs. The reads were aligned to the rat genome (version rn4 [Nov. 2004] , from UCSC Genome Browser [http://www.genome.ucsc.edu]) using Bowtie (0.12.7) 27 with Tophat (1.3.0). 28 We used Cufflinks 28 to first assemble transcripts from all data sets using the RefSeq gene annotation as a reference guide. All mouse and human XenoRefSeq annotations that overlapped with the unannotated transcripts were identified. Nonoverlapping transcripts were assessed for protein-coding potential using PhyloCSF 29 (Dr Michael F. Lin, Massachusetts Institute of Technology, Boston). Using a threshold previously used to identify noncoding RNAs, all multiexonic transcripts with a PhyloCSF score >20 were called novel protein-coding transcripts and <20 as lncRNAs. 29, 30 To assess the biological reproducibility between the replicates for each condition, fragments per kilobases per million reads were determined for all genes, and Pearson correlation value was determined for each gene (Online Figure III) . Cuffdiff was used to identify differentially expressed transcripts with the reference annotation containing rat RefSeq genes, homologous mouse and human XenoRefSeq genes, novel proteincoding transcripts, and lncRNAs with fragments per kilobases per million reads >0.5. Quantitative reverse transcriptase polymerase chain reaction (RT-PCR) was performed with ≥3 biological replicates of control and Ang II-treated cells to validate the changes in gene expression identified for 20 genes. Specifically, RNA was extracted, converted to cDNA (Taqman Kit, Applied Biosystems), and analyzed for transcript abundance using quantitative PCR (Kapa SYBR Green, Kapa Systems; AB7500, Applied Biosystems; primers [Online To assess the significance of the proximity of coregulated lncRNAs and protein-coding genes, we performed 100 000 simulations of proximity measurement on randomly placed coregulated lncRNAs and protein-coding genes in the rat genome. Specifically, we first placed 30 680 genes and 466 lncRNAs randomly across the 2 718 881 021 bp genome. We then randomly selected 467 of the genes and 24 of the lncRNAs to be coregulated and counted the number of simulated Ang II-regulated lncRNAs to be within 500 kb of a simulated Ang II-regulated gene. From this analysis, the empirical P value for 7 coregulated lncRNAs and protein-coding genes was 0.02734.
miRNA Expression and Transcript Analysis
Total RNA was extracted at the specified time points after Ang II treatment. miRNA cDNA was generated (qscript [Quanta Biosciences]) for quantitative PCR. miRNA levels were normalized to small RNA U6. For the analysis of miR-222 and miR-221 host transcript, cDNA was generated from total RNA using GeneRacer Kit (Life Technologies). Primers were generated to amplify transcripts containing miR-222-miR-221 in PCR reaction (Phusion Polymerase, Invitrogen). As a control, cDNA reaction was performed without reverse transcriptase, and genomic DNA was amplified as positive control.
Chromatin-Immunoprecipitation Sequencing
ChIPs were performed with an anti-H3K4me3 antibody (04-745, Millipore) and anti-H3K36me3 (ab9060, Abcam) using standard ChIP protocols. Twenty nanogram of ChIP DNA was prepared for sequencing on the Illumina GAII machine, which produced 42 bp reads. We obtained 44.5 mol/L reads for control-H3K4me3, 42.9 mol/L reads for control-H3K36me3, 48.7 mol/L reads for controlinput, 41.7 mol/L reads for Ang II-H3K4me3, 42.9 mol/L reads for Ang II-H3K36me3, and 48.2 mol/L reads for Ang II-Input. Bowtie was used to map the reads to the rat genome (rn4, UCSC Genome Browser), resulting in 33.2 mol/L reads for control-H3K4me3, 34.9 mol/L reads for control-H3K36me3, 37.3 mol/L reads for controlinput, 32.2 mol/L reads for Ang II-H3K4me3, 31.2 mol/L reads for Ang II-H3K36me3, and 36.4 mol/L reads for Ang II-input-≈70% of the reads aligned to the genome. Normalized profiles of histone modifications in promoter regions were performed as described previously. 31 RSEG was used to identify regions of the genome that are enriched for H3K4me3 and H3K36me3 compared with input samples using default parameters (bins with P<0.05 were defined as boundaries). 32 Genomic regions enriched for H3K4me3 and H3K36me3 in control and Ang II-treated samples were compared with the genomic coordinates for rat RefSeq genes, mouse and human XenoRefSeq genes, novel protein-coding transcripts, and lncRNAs. Any overlap between the modification enriched regions and the genes were determined to be positive enrichment of the modification at the gene.
Transfections
Small interfering RNA (siRNA) knockdown of Lnc-Ang362 performed using 1 million cells were transfected according to manufacturer protocol (Amaxa) using 50 nmol/L of a pool of siRNAs targeting Lnc-Ang362 or 50 nmol/L of control siRNAs (Non-Targeting Control, [NTC] Thermo Scientific). The algorithm GPboost was used to design siRNAs for targeting Lnc-Ang362 33 .
The pool of siRNA oligos are the following: 5′ -TTTCTCTGTACAAATGTCAUU-3′/5′ TGACATTTGTACAGA GAAAUU-3′, 5′-UUUCUGCCAUGACAUUUACUU-3′/5′ GUA AAUGUCAUGGCAGAAAUU-3′, 5′-UAAGCAGAUGAAUUCU AACUU-3′/5′-GUUAGAAUUCAUCUGCUUAUU-3′, 5′-TTT ATTTGTCAGAACCTTTUU-3′/5′-AAAGGTTCTGACAAAT AAAUU-3′, and 5′-TATTTCTCTGATAAAGCATUU-3′/5′ ATGCTTTATCAGAGAAATAUU-3′. Forty-eight hours after transfection, the cells were treated with Ang II for 3 hours, and RNA was collected by Trizol for standard quantitative RT-PCR analysis.
Cell Proliferation Assay
VSMCs were plated subconfluent for lipofectamine (Invitrogen) transfections with siRNAs (NTC or siRNAs targeting Lnc-Ang362). After 5 days, methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was performed. Briefly, 5 mg/mL of MTT dissolved in PBS was added to the media of the cells, cells were incubated for 3 hours to allow uptake of MTT, cells were then solubilized with 95% DMSO, and absorbance of the solution was measured.
Data Access
The data may be accessed at http://www.ncbi.nlm.nih.gov/geo/query/ acc.cgi?token=zvsnxeuosqymani&acc=GSE38056.
Results
Identification and Characterization of Novel lncRNAs in Rat VSMCs
To uncover the transcriptomic effects of Ang II, we treated rat VSMCs for 3 hours with Ang II and then performed RNA-seq of RNA isolated from control and Ang II-treated cells from 2 independently isolated biological replicates. Initial assessment of the data revealed that many sequencing reads, from both control and Ang II-treated cells, align to regions outside of gene annotated regions (Online Table I ). This was reminiscent of recent studies of the mouse and human genomes, which discovered many lowly expressed intergenic transcripts, many of which are lncRNAs. 16, 21, 22 Therefore, we identified all intergenic transcripts that are expressed in rat VSMCs. Transcripts were first assembled de novo, and multiexonic transcripts that did not overlap with known rat genes or homologous mouse and human genes were classified as novel ( Figure 1A ). We discovered 833 transcripts using this approach. We further classified them as protein-coding or noncoding by assessing their protein-coding potential. 29, 30 We classified 466 transcripts with limited protein-coding potential as lncRNAs and 367 as protein-coding transcripts ( Figure 1A , OnlineTables II-III).
A number of these transcripts are proximal (<500 kb) 34 to genes annotated previously. For example, RpcRNA-297 (rat protein-coding-RNA-297), a novel protein-coding RNA, and Lnc-Ang52 (Lnc-Ang52) are within 100 kb of Cpe and Fzd2, respectively ( Figure 1B and 1C ). In comparison with previously annotated rat genes, both novel protein-coding and lncRNAs are shorter in length and are less abundant (Figure 2A-2C) . The low abundance of lncRNAs is consistent with previously reported human and mouse lncRNA expression data. 21, 30 Evidence shows that certain chromatin modifications can be used to identify functional regions of the genome. 35 For example, studies have used histone H3K4me3, which is associated with transcriptional start sites (TSS), and histone H3K36me3, which is associated with gene bodies, to identify known as well as novel transcripts. 21 We performed, in parallel with the RNA-seq analysis, ChIP-seq to identify regions of the genome that were enriched with H3K4me3 and H3K36me3. 36, 37 As expected, in both control and Ang II-treated VSMCs, H3K4me3 is enriched near TSS, whereas H3K36me3 is enriched in gene bodies of annotated rat genes ( Figure 1B and 1C, Online Figure I ). We found that the majority of the novel loci are also enriched for both chromatin modifications at levels similar to rat gene loci annotated previously ( Figure 2D ). Eight percentage of the novel transcripts do not show enrichment of either modification. We hypothesized that these loci are transcribed at very low rates and correspondingly may be enriched for the modifications below our detection threshold. To test this, we separated annotated rat genes by their expression levels and assessed the enrichment of the 2 modifications. Genes with low expression levels are more likely to be devoid of these 2 modifications in line with our hypothesis (Online Figure II) . These data reveal that the novel loci have similar enrichment of chromatin modifications as previously annotated genes. Altogether, our analysis has identified novel protein-coding transcripts as well as lncRNAs, which are expressed in rat VSMCs.
Ang II-Regulated Transcript Expression in VSMCs
With the expanded list of rat gene annotation, which includes homologous human and mouse genes, and novel protein-coding and lncRNAs, we next identified genes that are regulated in an Ang II-dependent manner. For this analysis, we retained only those transcripts that were transcribed >0.5 fragments per kilobases per million reads in either control or Ang II-treated cells. Previous studies have used this cutoff and successfully identified lncRNAs associated with type 2 diabetes mellitus. 38 In total, from RNA-seq of 2 biological replicates of each condition, for which we found high correlation (Online Figure III) , 491 genes are differentially expressed in the Ang II-treated VSMCs with 331 that are Ang II upregulated and 160 transcripts that are downregulated (P<0.05; false discovery rate adjusted with Benjamini-Hochberg; Figure 3A , Online Table IV ). Of those, 5 previously annotated lncRNAs and 24 novel lncRNAs are Ang II regulated (19 upregulated, 5 downregulated). We also find 14 novel protein-coding transcripts are Ang II regulated. To validate the expression profiles generated from the RNA-seq, we performed quantitative RT-PCR analysis on 20 differentially expressed genes and found high correlation between the 2 data sets Figure 3B , Online Figure IV ). Within the list of genes defined as differentially expressed, a number of proinflammatory and profibrotic genes (eg, Mcp1 and Serpine1 [Pai-1]) were identified consistent with previous reports 3, 39 ( Figure 3C , Online Table IV ). Our combined RNA-seq/ChIP-seq analyses also revealed previously unknown Ang II-regulated genes, such as Adamts15, proximal to the rat homolog of human ADAMTS8 ( Figure 3D ), and Hivep3 ( Figure 3E ). Expression of Adamts15 is downregulated, whereas Hivep3 is dramatically upregulated. Interestingly, it has previously been shown that Hivep3 contains many alternative isoforms and uses different promoters for transcription of its different isoforms. 40 In our H3K4me3 data, we observed 2 distinct regions that are enriched for H3K4me3, suggesting that those are the promoters that are used in VSMCs. Thus, RNA-seq identified previously known and unknown transcripts regulated by Ang II. Interestingly, on close inspection, the RNA-seq data contained many intronic reads, such as those observed at the Serpine1 (Pai-1) locus, which potentially represent nascent transcripts, yet to be spliced cotranscriptionally, as described recently. 41
Ang II-Upregulated Gene Loci Exhibit Increased Enrichment of H3K4me3 and H3K36me3
To characterize the changes occurring at the chromatin level induced by Ang II, we assessed the enrichment of H3K4me3 and H3K36me3 in both control and Ang II-treated VSMCs. As noted above, H3K4me3 is enriched near the TSS, whereas H3K36me3 is enriched in gene bodies (Online Figure I) . We analyzed the enrichment of these marks at loci of genes with increased transcript abundance identified by the gene expression profiling. We first ranked the genes by their fold change in cells treated with Ang II relative to control cells, and then compared the enrichment of H3K4me3 surrounding the TSS and H3K36me3 across the gene body for each differentially expressed gene ( Figure 4A ). Compared with the Ang II-downregulated loci, Ang II-upregulated gene loci exhibit increased enrichment of H3K4me3 and H3K36me3 ( Figure 4B and 4C) . The ChIP-seq data were validated by follow-up ChIP-quantitative PCRs on a set of differentially modified regions (Online Figure V) . These data indicate that methylation of H3K4 and H3K6 accompany most increases in transcript abundance, indicating changes in transcriptional rate in response to Ang II.
lncRNA Expression Is Dynamic With Ang II Treatment, and Effects Are Recapitulated Ex Vivo
To further validate the regulation of key lncRNAs by Ang II, we analyzed the time course of expression of 2 downregulated lncRNAs, Lnc-Ang219 and lncRNA-Ang249, and 3 upregulated lncRNAs, Lnc-Ang362, Lnc-Ang162, and Lnc-Ang112 ( Figure 5A and 5B, n=5 ). The abundance of both that the expression of these lncRNAs in response to Ang II is dynamic. We next examined whether these observations in vitro could be recapitulated ex vivo. Aortas were isolated and treated with Ang II, and expression of the lncRNAs was assessed (n=6). Indeed, with Ang II treatment, Lnc-Ang362 (6 hours), Lnc-Ang112 (3, 6, and 24 hours), and Lnc-Ang162 (6 hours) are upregulated, whereas Lnc-Ang219 (3 hours) and Lnc-Ang249 (3, 6, and 24 hours) are downregulated ( Figure 5C and 5D ; P<0.05).
A Key Biological Function of an Ang II-Regulated lncRNA Is Cotranscription With miRNAs and Alteration of VMSC Proliferation
Previous analyses of lncRNAs have indicated that they are often coregulated with neighboring genes and can have enhancer-like activities. 22, 34 We found that 7 of our differentially expressed lncRNAs are proximal (<500 kb) to genes expressed differentially (Table; P<0.05, all adjacent genes can be found in Online Table V) . Six of these lncRNAs are regulated by Ang II in the same direction as the proximal gene in our RNAseq data set.
Within this list is Lnc-Ang362, an Ang II-upregulated lncRNA proximal to miR-221 and miR-222 ( Figure 6A ). Previous studies have shown these 2 miRNAs are involved in VSMC proliferation and are upregulated in response to Ang II in endothelial cells to promote inflammation and migration. 25, 26 Our RNA-seq analysis did not identify miR-221 or miR-222 because our method of RNA-seq does not assess small RNAs. To verify whether these miRNAs are upregulated in response to Ang II, we assessed the expression of mature miR-222 and miR-221 by quantitative RT-PCR. We found that these miR-NAs are indeed upregulated ( Figure 6B; miR-222, 3 and 6  hours, and miR-221, 6 hours, P<0.05, n=5) . Furthermore, we found that the mature miRNAs are also upregulated with Ang II treatment of aortas ex vivo ( Figure 6C, miR-222 and miR-221 3, 6, and 24 hours, n=6, P<0.05). These data indicate that the regulation of the mature miRNAs by Ang II in vitro is recapitulated ex vivo. Interestingly, miR-221/miR-222 locus is not enriched for H3K4me3, suggesting that the initiation of transcription for these 2 miRNAs is further upstream ( Figure 6A ). The closest region enriched for H3K4me3 upstream from the miRNAs is located at the TSS for Lnc-Ang362. LncRNAs, including the H19 RNA that is involved in imprinting and X chromosome inactivation, 42 have been shown to encode miR-NAs. Therefore, we hypothesized that the 2 miRNAs are cotranscribed with Lnc-Ang362, and we decided to test whether the miRNAs are transcribed as part of a larger transcript. PCR amplification of cDNA from VSMCs using primers surrounding the miRNA locus ( Figure 6D) shows that the miRNAs are indeed transcribed as part of a larger transcript ( Figure 6E ). Furthermore, the abundance of this transcript is, as posited, increased by Ang II and in a time-dependent manner. We were further able to amplify an ≈6-kb amplicon from cDNA containing the 2 miRNAs and the 3′ end of Lnc-Ang362 (Online Figure VI) . This suggests that the miR-221 and miR-222 are cotranscribed with Lnc-Ang362, the host transcript from which these miRNAs are excised, and that the transcription initiation site to produce the 2 miRNAs is further upstream. We next assessed whether the expression of Lnc-Ang362 is necessary for the expression of the mature miRNAs during Ang II treatment by evaluating the effects of siRNA knockdown of Lnc-Ang362. Transfection of VSMCs with specific siRNAs designed using the GPboost algorithm 33 targeting Lnc-Ang362 was able to attenuate the expression significantly of the mature miRNAs, miR-221 and miR-222 ( Figure 7A;  P<0.05; n=3 ). Furthermore, we evaluated the functional consequences of this knockdown by assessing the rates of proliferation of VSMCs transfected with siRNAs targeting Lnc-Ang362. Results showed that these cells proliferate to a lesser extent than VSMCs transfected with control siRNAs ( Figure 7B; P<0.05; n=6 ), suggesting that the lncRNA plays a role in VSMC growth. Furthermore, knockdown of Lnc-Ang362 produced a significant reduction in the expression of Mcm7 (Figure 7C; P<0.05; n=3) , a member of the minichromosome maintenance protein complex, which contains DNA helicase activity required for the initiation of DNA replication and cell cycle progression. 43 Expression of minichromosome maintenances have previously been shown to be induced by Ang II in human VSMCs, and we also observed this in rat VSMCs (not shown). 44 Because miR-222 and miR-221 are known to play a role in proliferation of VSMCs, the effects of Lnc-Ang362 on proliferation may likely be through its role as the host transcript for the 2 miRNAs. Interestingly, maps of H3K4me3 from various mouse and human cells show that this chromatin modification is not enriched at the locus encoding for miR-222/miR-221 but is enriched ≈25-kb upstream from them even in these cells (Online Figure VII) . 45, 46 This suggests that the function of the lncRNA may be conserved in human and mice.
Discussion
The profiling approaches used in this study have led to several novel discoveries in rat genomics, VSMC and Ang II-mediated gene regulation. Because rats are a widely used model organism for research related to CVDs, diabetes mellitus, and other pathologies, it is imperative to analyze their transcriptome in-depth. Our annotation of novel transcripts significantly expands the existing number of known transcripts expressed in the rat genome, which, compared with the human and mouse genomes, remains less well annotated. We found that, similar to mouse and human, the rat genome contains lncRNAs that are less abundantly expressed than previously annotated rat transcripts. 22 Notably, our studies revealed that the identified lncRNAs may function as host transcripts for small RNAs, such as miRNAs. Our analysis of the transcriptome and epigenome associated with H3K4me3 and H3K36me3 uncovered that Lnc-Ang362 is proximal to miR-221 and miR-222. Based on the enrichment of H3K4me3, which is at the TSS of Lnc-Ang362, but not at the locus containing the 2 miRNAs, we speculated that the lncRNA and miRNAs are coregulated, and that Lnc-Ang362 is the host transcript for the 2 miRNAs. Indeed with knockdown studies, we found that the miRNAs are transcribed as a large transcript that is Ang II regulated, and *miR-221 and miR-222 have been assessed by quantitative RT-PCR ( Figure 6 ). Shown are FPKM for each transcript in control and Ang II-treated VSMCs (±95% confidence intervals) and the fold change (Log 2 ) with the P adjusted for FDR with Benjamini-Hochberg.
that Lnc-Ang362 is required for the expression of the 2 miR-NAs. We also found that Lnc-Ang362 affects cell proliferation and expression of a critical component of cell cycle progression, Mcm7, presumably through its effects on the miRNAs. Additionally, this reveals that the transcription initiation site for the production of the 2 miRNAs (miR-221 and miR-222) is further upstream than would be expected, and that this may be conserved in human and mice based on enrichment profiles of H3K4me3. It is worth noting that the H3K4me3 domain related to miR-132 and miR-212, which we had previously discovered to be regulated by Ang II, 15 is on the contrary, very proximal to the locus containing the miRNAs (Online Figure   VIII ). Further analysis in the regulation of transcription initiation at the TSS of Lnc-Ang362 will provide pertinent information on how the 2 miRNAs and Lnc-Ang362 are specifically regulated during VSMC proliferation. It is also possible that the host Lnc-Ang362 has miRNA-independent effects. To date, only a few studies have reported functional roles of ln-cRNAs attributable to their long size and secondary structure, which makes it more difficult to target with siRNAs or generate expression vectors. 47 In addition to functioning as host transcripts for miRNAs, lncRNAs may function as enhancers and regulate the expression of proximal genes. 34, 48 We discovered many novel lncRNAs that are differentially expressed by Ang II and are proximal to other transcripts that are also Ang II regulated. Studies investigating coregulation of lncRNAs with their neighbors and whether this occurs via alterations of enhancer chromatin modifications will be informative in understanding the role of lncRNAs in Ang II effects. We also provide genome-wide enrichment profiles of H3K4me3 and H3K36me3 in control and Ang II-treated VSMCs. We found that genomic regions with upregulated transcripts are more enriched for these 2 modifications with Ang II than genomic regions with downregulated transcripts. This is consistent with the idea that the increase in transcript abundance is generally regulated at the transcriptional level, which in turn is associated with increase in H3K4me3 and H3K36me3. By comparison, downregulation of genes with Ang II is not accompanied by a marked decrease of H3K4me3 or H3K36me3. This could be attributable to a number of scenarios: (1) if the downregulation of transcript abundance is at the transcriptional level, then these results would indicate that the removal of H3K4me3 and H3K36me3 is not as dynamic as their addition at 3 hours, or (2) the transcript abundance is regulated at a post-transcriptional level, such as miRNAdirected degradation or mRNA stability. Similar lack of decrease in histone methylation has previously been observed in other systems as well. 49 It is likely that a combination of these scenarios is functioning in response to Ang II.
Notably, this is the first study to profile the expression of transcripts by high-throughput sequencing methods in VSMCs and their response to Ang II. We were able to identify new genes regulated by Ang II. One of these is Adamts15, which encodes for a disintegrin and metalloproteinase with thrombospondin motifs protein. A disintegrin and metalloproteinase with thrombospondin motifs family members have been found to play a role in VSMC migration and invasion. 50 Low expression of ADAMTS15 has been suggested to be involved in colorectal, breast, and prostate cancer, perhaps through a transforming growth factor-β signaling mechanism. 51, 52 Interestingly, although Adamts15 is proximal to Adamts8, Ang II only reduces the expression of Adamts15 and not Adamts8. Comparing the regulation of Adamts15 with its family members may identify key features, such as transcription factor networks that regulate a disintegrin and metalloproteinase with thrombospondin motifs proteins in response to Ang II. Our data set also revealed that 1 of the novel genes highly induced by Ang II is Hivep3 (also known as Zas3/KRC/Shn-3), a member of the Shnurri family of proteins, which encodes for a transcription factor known to bind to nuclear factor-κB motifs and modulate the effects of nuclear factor-κB on gene expression. 53 This gene plays a key role in osteogenesis, vascular calcification, and bone resorption, 54, 55 but the precise role of Hivep3 in VSMCs and on Ang II effects has not been explored. Investigations into the role of Adamts15 and Hivep3 have the potential to elucidate novel gene targets and molecular mechanisms that mediate Ang II effects. Furthermore, we cross-referenced human genes previously associated with CVDs and cardiovascular traits and found that a number of them are among the genes that we identified to be regulated by Ang II (Online Table VI ). This suggests that the genes may potentially be involved in the vascular effects of Ang II. Further investigations will be necessary to examine these interesting correlations and the role of these genes in Ang II biology.
Taken together, this study provides an in-depth view into the transcriptome of rat cells that has led to the first elucidation of novel genes and lncRNAs regulated by Ang II. These transcripts represent potential new avenues of research into how VSMCs respond to vasoactive stimuli like Ang II and, ultimately, promote CVDs.
